LONDON (Alliance News) - GlaxoSmithKline PLC said Tuesday that its joint venture Viiv Healthcare Ltd saw its Tivicay integrase inhibitor approved for use in combination with other anti-retroviral medicinal products for the treatment of HIV by the European Commission.
This regulation authorises the treatment to be marketed in every member state of the European Union.
GlaxoSmithKline established ViiV Healthcare along with Pfizer Inc in 2009 to tackle the treatment of HIV, Shionogi Ltd took a 10% interest in the company in October 2012.
Shares in Glaxo were trading up 0.6%, or 10.24 pence, at 1,673.24 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @hanassallnews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)